In the emerging framework, a medicine’s value will increasingly depend on how effectively care is delivered around it’ ...

For decades, the rate of spontaneous preterm birth in the United States has hovered stubbornly around 10%. Despite advancements in other areas of medicine, prematurity remains the second leading cause ...

Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal valued at up to $7bn, as the company looks to expand its capabilities in cell and gene therapy. Under the terms of the agreement, Kelonia ...

Zymeworks, a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and ...